Frederick Howard, MD, explored the evolving intersection of artificial intelligence (AI), computational pathology, and precision breast oncology.
|Articles|June 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 6
- Volume 15
- Issue 6
Phase I Trial of NPI-0052 Begins
Nereus Pharmaceuticals, Inc. has initiated a phase I trial of its novel, small molecule proteasome inhibitor, NPI-0052, in patients with solid tumors and lymphomas. The trial will enroll approximately 50 patients at two sites, M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. NPI-0052 was discovered during the fermentation of Salinispora sp, a new class of Gram-positive marine bacteria, Nereus said in a press release.
Advertisement
SAN DIEGO, CalifNereus Pharmaceuticals, Inc. has initiated a phase I trial of its novel, small molecule proteasome inhibitor, NPI-0052, in patients with solid tumors and lymphomas. The trial will enroll approximately 50 patients at two sites, M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. NPI-0052 was discovered during the fermentation of Salinispora sp, a new class of Gram-positive marine bacteria, Nereus said in a press release.
Articles in this issue
over 20 years ago
Triple-Negative Cancers More Common in Young Black Ptsover 20 years ago
Artists Turn Flowers & Curves Into 'Forms' and 'Figures'over 20 years ago
Study to Examine Outcomes Disparities in Pediatric ALLover 20 years ago
Thalidomide Has 'Changed the Paradigm' in Myeloma Rxover 20 years ago
CA4P Gets Orphan Drug Statusover 20 years ago
Testicular Ca Survivors at Increased Risk for CV Eventsover 20 years ago
A Novel Brings a Cancer Research Laboratory to Lifeover 20 years ago
NCCN Reveals New Venous Thromboembolism Guidelineover 20 years ago
Lapatinib New Option for Metastatic HER2+ Breast Caover 20 years ago
FDA Approves Dacogen for Treating All MDS SubtypesAdvertisement
Related to this article
“Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon).
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal cancer.
Investigators will share detailed findings from the phase 1a/b EMBOLD PanTumour-101 study at the European Society for Medical Oncology Congress 2026.
The anti–IL-1α antibody vilamakitug added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.
Long-term QUILT-3.032 data showed a 71% CR rate, with a median duration of 26.6 months with nogapendekin alfa inbakicept/BCG in BCG-unresponsive NMIBC.
The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk non–muscle invasive bladder cancer.
Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer
2
Ris-Rez Produces Anti-Tumor Activity in Extensive-Stage SCLC
3
Is Vitamin C an Epigenetic Interception Strategy in Pre-Leukemic Disease?
4
AI Foundation Models & Molecular Biomarkers in Breast Cancer
5